Workflow
滴丸剂
icon
Search documents
力生制药9月17日获融资买入809.60万元,融资余额3.10亿元
Xin Lang Cai Jing· 2025-09-18 01:29
Group 1 - On September 17, Lisheng Pharmaceutical's stock fell by 1.20%, with a trading volume of 87.40 million yuan [1] - The financing data shows that on the same day, Lisheng Pharmaceutical had a financing purchase amount of 8.10 million yuan and a financing repayment of 16.16 million yuan, resulting in a net financing outflow of 8.06 million yuan [1] - As of September 17, the total balance of margin trading for Lisheng Pharmaceutical was 310 million yuan, accounting for 5.21% of its circulating market value, which is above the 90th percentile of the past year [1] Group 2 - As of August 20, the number of shareholders of Lisheng Pharmaceutical was 31,200, a decrease of 0.39% from the previous period, while the average circulating shares per person increased by 0.39% to 8,017 shares [2] - For the first half of 2025, Lisheng Pharmaceutical achieved an operating income of 732 million yuan, a year-on-year decrease of 1.76%, while the net profit attributable to the parent company was 343 million yuan, a year-on-year increase of 235.04% [2] Group 3 - Since its A-share listing, Lisheng Pharmaceutical has distributed a total of 1.261 billion yuan in dividends, with 255 million yuan distributed in the last three years [3] - As of June 30, 2025, Dazheng Jingheng Mixed A (090019) has exited the list of the top ten circulating shareholders of Lisheng Pharmaceutical [3]
天目药业: 杭州天目山药业股份有限公司章程(2025年8月修订)
Zheng Quan Zhi Xing· 2025-08-27 10:06
Group 1 - The company, Hangzhou Tian-Mu-Shan Pharmaceutical Co., Ltd., was established as a pilot unit for state-owned enterprise reform in October 1989 and has undergone several regulatory updates since then [2][3][4] - The registered capital of the company is RMB 121.78 million, and it operates as a permanent joint-stock company [4][5] - The company aims to develop a modern enterprise group with first-class economic benefits and products, focusing on pharmaceutical production and diversified development [3][4] Group 2 - The company has established a party organization to play a political core role and provide political guidance in its development [2] - The company’s business scope includes the production of various pharmaceutical forms, health foods, medical devices, and cosmetics, among others [3][4] Group 3 - The company issues shares in the form of stocks, with each share having a face value of RMB 1 [4][5] - The total number of shares issued by the company is 121,778,885, all of which are ordinary shares [4][5] Group 4 - The company is prohibited from providing financial assistance for others to acquire its shares, except under specific circumstances approved by the shareholders' meeting [5][6] - The company can reduce its registered capital following legal procedures and shareholder approval [6][7] Group 5 - The company’s shareholders have rights to dividends, voting, and other benefits proportional to their shareholdings [10][11] - Shareholders holding more than 5% of the shares must declare their holdings and any changes [8][9] Group 6 - The company’s shareholders' meeting is the authority of the company, responsible for electing directors, approving financial reports, and making significant corporate decisions [18][19] - The company must hold an annual shareholders' meeting within six months after the end of the previous fiscal year [21][22]